183 related articles for article (PubMed ID: 36006678)
1. Creating and Implementing a Principal Investigator Tool Kit for Enhancing Accrual to Late Phase Clinical Trials: Development and Usability Study.
Higgins KA; Thomas A; Soto N; Paulus R; George TJ; Julian TB; Hartson Stine S; Markham MJ; Werner-Wasik M
JMIR Cancer; 2022 Aug; 8(3):e38514. PubMed ID: 36006678
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy Standardisation and Artificial Intelligence within the National Cancer Institute's Clinical Trials Network.
Lee SH; Geng H; Xiao Y
Clin Oncol (R Coll Radiol); 2022 Feb; 34(2):128-134. PubMed ID: 34906407
[TBL] [Abstract][Full Text] [Related]
4. Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP-sponsored clinical trials before and after launch of the NCI National Clinical Trials Network.
Sankaran H; Finnigan SR; McShane LM; Best AF; Seibel NL
Cancer; 2022 Nov; 128(21):3843-3849. PubMed ID: 36089859
[TBL] [Abstract][Full Text] [Related]
5. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade.
Peters GW; Tao W; Wei W; Miccio JA; Jethwa KR; Cecchini M; Johung KL
Oncologist; 2021 Aug; 26(8):660-667. PubMed ID: 33728733
[TBL] [Abstract][Full Text] [Related]
6. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.
Bennette CS; Ramsey SD; McDermott CL; Carlson JJ; Basu A; Veenstra DL
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26714555
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
[TBL] [Abstract][Full Text] [Related]
8. The Successful Synchronized Orchestration of an Investigator-Initiated Multicenter Trial Using a Clinical Trial Management System and Team Approach: Design and Utility Study.
Mudaranthakam DP; Brown A; Kerling E; Carlson SE; Valentine CJ; Gajewski B
JMIR Form Res; 2021 Dec; 5(12):e30368. PubMed ID: 34941552
[TBL] [Abstract][Full Text] [Related]
9. Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602).
Freedman RA; Dockter TJ; Lafky JM; Hurria A; Muss HJ; Cohen HJ; Jatoi A; Kemeny MM; Ruddy KJ
Oncologist; 2018 Sep; 23(9):1016-1023. PubMed ID: 29674441
[TBL] [Abstract][Full Text] [Related]
10. Monitoring Twitter Conversations for Targeted Recruitment in Cancer Trials in Los Angeles County: Protocol for a Mixed-Methods Pilot Study.
Reuter K; Angyan P; Le N; MacLennan A; Cole S; Bluthenthal RN; Lane CJ; El-Khoueiry AB; Buchanan TA
JMIR Res Protoc; 2018 Sep; 7(9):e177. PubMed ID: 30274964
[TBL] [Abstract][Full Text] [Related]
11. Increasing Minority Enrollment Onto Clinical Trials: Practical Strategies and Challenges Emerge From the NRG Oncology Accrual Workshop.
Brooks SE; Muller CY; Robinson W; Walker EM; Yeager K; Cook ED; Friedman S; Somkin CP; Brown CL; McCaskill-Stevens W
J Oncol Pract; 2015 Nov; 11(6):486-90. PubMed ID: 26464496
[TBL] [Abstract][Full Text] [Related]
12. Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.
Mitchell AP; Hirsch BR; Abernethy AP
Trials; 2014 Mar; 15():92. PubMed ID: 24661848
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Barriers to Pediatric Oncologist Engagement and Accrual to Clinical Trials in National Cancer Institute-Designated Community Oncology Research Programs.
Dickens DS; Roth ME; Pollock BH; Langevin AM
JCO Oncol Pract; 2020 Oct; 16(10):e1060-e1066. PubMed ID: 32396490
[TBL] [Abstract][Full Text] [Related]
14. Time to publication of oncology trials and why some trials are never published.
Chapman PB; Liu NJ; Zhou Q; Iasonos A; Hanley S; Bosl GJ; Spriggs DR
PLoS One; 2017; 12(9):e0184025. PubMed ID: 28934243
[TBL] [Abstract][Full Text] [Related]
15. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
16. NCTN clinical trial standardization for radiotherapy through IROC and CIRO.
Zou W; Geng H; Teo BK; Finlay J; Xiao Y
Med Phys; 2018 Oct; 45(10):e850-e853. PubMed ID: 30151925
[TBL] [Abstract][Full Text] [Related]
17. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
Schroen AT; Petroni GR; Wang H; Thielen MJ; Sargent D; Benedetti JK; Cronin WM; Wickerham DL; Wang XF; Gray R; Cohn WF; Slingluff CL; Djulbegovic B
Clin Trials; 2011 Oct; 8(5):591-600. PubMed ID: 21878447
[TBL] [Abstract][Full Text] [Related]
18. Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.
Khunger M; Rakshit S; Hernandez AV; Pasupuleti V; Glass K; Galsky MD; Grivas P
Oncologist; 2018 Dec; 23(12):1494-1499. PubMed ID: 30068783
[TBL] [Abstract][Full Text] [Related]
19. Creating a "culture of research" in a community hospital: Strategies and tools from the National Cancer Institute Community Cancer Centers Program.
Dimond EP; St Germain D; Nacpil LM; Zaren HA; Swanson SM; Minnick C; Carrigan A; Denicoff AM; Igo KE; Acoba JD; Gonzalez MM; McCaskill-Stevens W
Clin Trials; 2015 Jun; 12(3):246-56. PubMed ID: 25691600
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
